PT1201639E - Compostos de lipoxina e sua utilização no tratamento de distúrbios proliferativos celulares - Google Patents

Compostos de lipoxina e sua utilização no tratamento de distúrbios proliferativos celulares Download PDF

Info

Publication number
PT1201639E
PT1201639E PT02001564T PT02001564T PT1201639E PT 1201639 E PT1201639 E PT 1201639E PT 02001564 T PT02001564 T PT 02001564T PT 02001564 T PT02001564 T PT 02001564T PT 1201639 E PT1201639 E PT 1201639E
Authority
PT
Portugal
Prior art keywords
cell proliferative
proliferative disorders
treating cell
lipoxin compounds
compounds
Prior art date
Application number
PT02001564T
Other languages
English (en)
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of PT1201639E publication Critical patent/PT1201639E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT02001564T 1996-09-13 1997-09-15 Compostos de lipoxina e sua utilização no tratamento de distúrbios proliferativos celulares PT1201639E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/712,610 US6048897A (en) 1993-06-15 1996-09-13 Lipoxin compounds and their use in treating cell proliferative disorders

Publications (1)

Publication Number Publication Date
PT1201639E true PT1201639E (pt) 2008-10-03

Family

ID=24862848

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02001564T PT1201639E (pt) 1996-09-13 1997-09-15 Compostos de lipoxina e sua utilização no tratamento de distúrbios proliferativos celulares
PT97941078T PT927150E (pt) 1996-09-13 1997-09-15 Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT97941078T PT927150E (pt) 1996-09-13 1997-09-15 Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares

Country Status (11)

Country Link
US (9) US6048897A (pt)
EP (3) EP1201639B1 (pt)
JP (1) JP4060366B2 (pt)
AT (2) ATE215924T1 (pt)
AU (1) AU723321B2 (pt)
CA (1) CA2265708C (pt)
DE (2) DE69738918D1 (pt)
DK (2) DK0927150T3 (pt)
ES (2) ES2312499T3 (pt)
PT (2) PT1201639E (pt)
WO (1) WO1998011049A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
CZ302691B6 (cs) * 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
EP1616566A1 (en) * 1999-03-18 2006-01-18 The Brigham And Women's Hospital, Inc. Lipoxin compounds for treating TNF-alpha initiated inflammation
JP2002539181A (ja) * 1999-03-18 2002-11-19 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物およびこれらの使用
CA2367909C (en) 1999-03-18 2008-02-12 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
AU2004235617B2 (en) * 1999-03-18 2008-06-05 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
EP1586550A1 (en) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
ATE258791T1 (de) * 1999-11-09 2004-02-15 Alcon Inc Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) * 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
WO2002070068A2 (en) * 2001-03-02 2002-09-12 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
ES2344814T3 (es) * 2001-03-02 2010-09-07 The Brigham And Women's Hospital Analogos de lipoxina como nuevos inhibidores de la angiogenesis.
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20030166716A1 (en) * 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
CA2467580C (en) 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
EP1941875B1 (en) * 2001-12-18 2012-09-12 The Brigham and Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DE60330154D1 (de) * 2002-08-12 2009-12-31 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
PL1809270T3 (pl) * 2004-11-09 2010-08-31 Alcon Inc Kwas 5,6,7-trihydroksyheptanowy i jego analogi do leczenia chorób oczu i chorób związanych z odpowiedziami hiperproliferacyjnymi i angiogenicznymi
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8245230B2 (en) * 2005-03-14 2012-08-14 Qnx Software Systems Limited Adaptive partitioning scheduler for multiprocessing system
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US20100029504A1 (en) 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
PE20081200A1 (es) 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
JP2009026126A (ja) * 2007-07-20 2009-02-05 Nec Electronics Corp 半導体装置
CN101843622B (zh) * 2010-04-27 2011-09-14 黄波 脂氧素在制备女性避孕药物中的应用
US9439966B2 (en) 2011-10-12 2016-09-13 Case Western Reserve University Multi-component nanochains
EP2917738A1 (de) 2012-11-12 2015-09-16 BIOCRATES Life Sciences AG Verwendung von qualitätsindikatoren zum nachweis von auftauprozessen in gefrorenen gewebeproben
CN105439813B (zh) * 2014-08-08 2017-10-27 广州丹康医药生物有限公司 化合物的合成方法
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
US11592453B2 (en) 2016-11-22 2023-02-28 The Brigham And Women's Hospital, Inc. Personalized metabolomic profiling of specialized pro-resolving mediators
WO2018161175A1 (en) 2017-03-09 2018-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2020150740A1 (en) 2019-01-18 2020-07-23 Case Western Reserve University Psma ligand targeted compounds and uses thereof
WO2022006470A1 (en) 2020-07-01 2022-01-06 Vanderbilt University Methods of treatment for a kidney disease
US12521435B2 (en) 2020-07-03 2026-01-13 Case Western Reserve University Photodynamic therapy composition
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) * 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) * 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) * 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
DE69435125D1 (de) * 1993-06-15 2008-10-02 Brigham & Womens Hospital Lipoxinverbindungen mit verlängerter halbwertszeit
WO1995001179A1 (en) 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5998487A (en) 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
CA2339049C (en) 1998-09-08 2010-02-23 Cornell Research Foundation, Inc. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease

Also Published As

Publication number Publication date
CA2265708A1 (en) 1998-03-19
JP4060366B2 (ja) 2008-03-12
DE69711894D1 (de) 2002-05-16
DE69711894T2 (de) 2002-11-14
ES2175460T3 (es) 2002-11-16
WO1998011049A1 (en) 1998-03-19
US6316648B1 (en) 2001-11-13
EP1201639A3 (en) 2003-01-02
US20020010351A1 (en) 2002-01-24
US6653493B2 (en) 2003-11-25
DK0927150T3 (da) 2002-07-22
DK1201639T3 (da) 2008-11-24
EP0927150A1 (en) 1999-07-07
ATE215924T1 (de) 2002-04-15
ATE404522T1 (de) 2008-08-15
AU723321B2 (en) 2000-08-24
US20020111505A1 (en) 2002-08-15
US20030134901A1 (en) 2003-07-17
US6569075B2 (en) 2003-05-27
PT927150E (pt) 2002-08-30
EP0927150B1 (en) 2002-04-10
US20020082435A1 (en) 2002-06-27
EP1201639A2 (en) 2002-05-02
EP2058293A1 (en) 2009-05-13
US6048897A (en) 2000-04-11
CA2265708C (en) 2003-06-10
AU4271097A (en) 1998-04-02
JP2001500866A (ja) 2001-01-23
DE69738918D1 (de) 2008-09-25
US20010031882A1 (en) 2001-10-18
US20020091279A1 (en) 2002-07-11
US6620919B2 (en) 2003-09-16
US6635776B2 (en) 2003-10-21
US6750360B2 (en) 2004-06-15
EP1201639B1 (en) 2008-08-13
US20030032827A1 (en) 2003-02-13
ES2312499T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
PT1201639E (pt) Compostos de lipoxina e sua utilização no tratamento de distúrbios proliferativos celulares
ZA96528B (en) 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
PT703897E (pt) Compostos de lipoxina com uma semi-vida prolongada
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
PL344304A1 (en) Combination therapy for treatment of bipolar disorders
AU3142597A (en) Dha-pharmaceutical agent conjugates
EP0682517A4 (en) PHOTODYNAMIC TREATMENT OF JOINT DISEASES
AU2592600A (en) Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
AU6256996A (en) Use of vitamin D4 derivatives for treating skin disorders
ZA975470B (en) Insulin preparations containing naci.
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
AU6857887A (en) Therapeutic agent
AU4830097A (en) Use of an extract of Cimicifuga
AU4008597A (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
ZA971891B (en) Use of aryl N-substituted carboxamides directly and as radio- and chemosensitizers for killing tumor and cancer cells and novel compounds for such use
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
BG101126A (en) The use of muramylpeptide compounds
EP0369216A3 (en) Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
IL133141A0 (en) Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
UA8280A (uk) Спосіб лікування псоріазу
BG102974A (en) Ethene-containing solutions and their use in methods of treatment or prevention